EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Improving Hereditary Cancer Risk Assessment: Systematic Reanalysis Supports Multigene Cancer Predisposition Panel Over Single Cancer Panel

Yinghong Pan, Patrick Danley, Evan Powell, Gregory Humphreys, Adalena Nanni, Marianne Mcguire, Tamar Kramer, Phuong L. Mai, Alexander Yatsenko, Daniel Bellissimo, Fen Guo

Human Mutation · 2026-01 · 2026 (1)

DOI: 10.1155/humu/6594805 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Mutation, online erschienen am 19.11.2026. Verfasst von Yinghong Pan und 10 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Next‐generation sequencing (NGS) enables the simultaneous sequencing of a considerable number of hereditary cancer predisposition genes efficiently. This study evaluated the clinical utility of multiple‐cancer predisposition panel (MCP) testing versus single/specific‐cancer panel (SCP) testing for hereditary cancers in our laboratory between 2020–2025. Testing indications included hereditary breast, ovarian, endometrial, gastrointestinal, pancreatic, prostate, melanoma cancers, and Lynch syndrome. A total of 2850 cases, which were initially ordered for SCP testing and later were reanalyzed for a larger SCP or a MCP, were included in this analysis. The reanalysis was requested by providers mostly because of insurance authorization only allowing a SCP and/or patient personal and family history including multiple cancers. The overall diagnostic yield for the initial SCP is 6% (176/2850). All the positive findings identified by the initial testing were detected by reanalysis, and the overall diagnostic yield for the reanalysis is 10% (285/2850), including 12 cases with multiple molecular diagnoses. The diagnostic rate varies depending on the cancer type and panel tested. In general, the MCP with more genes had higher yields. A total of 194 unique pathogenic or likely pathogenic (P/LP) single‐nucleotide variants and 20 copy number variants were reported. The most frequently identified genes causing diseases in this cohort include CHEK2 , BRCA2 , BRCA1 , ATM , MUTYH , PALB2 , BRIP1 , and MSH6 , which are all identifiable by the MCPs while may be missing from the initial selected SCPs. Our findings demonstrate that MCP outperforms SCP and supports professional society guidelines recommending medically actionable, high‐prevalence gene testing in germline cancer evaluation. We therefore propose MCP as a first‐tier test for hereditary cancer, as it improves diagnostic yield and enables faster, more comprehensive molecular assessment for patient risk management.

Zitieren

APA

Pan, Y., Danley, P., Powell, E., Humphreys, G., Nanni, A., Mcguire, M., Kramer, T., Mai, P. L., Yatsenko, A., Bellissimo, D., & Guo, F. (2026). Improving Hereditary Cancer Risk Assessment: Systematic Reanalysis Supports Multigene Cancer Predisposition Panel Over Single Cancer Panel. Human Mutation, 2026(1). https://doi.org/10.1155/humu/6594805

Vancouver

Pan Y, Danley P, Powell E, Humphreys G, Nanni A, Mcguire M, et al. Improving Hereditary Cancer Risk Assessment: Systematic Reanalysis Supports Multigene Cancer Predisposition Panel Over Single Cancer Panel. Human Mutation. 2026;2026(1). doi:10.1155/humu/6594805

BibTeX
@article{Pan2026,
  author = {Pan, Yinghong and Danley, Patrick and Powell, Evan and Humphreys, Gregory and Nanni, Adalena and Mcguire, Marianne and Kramer, Tamar and Mai, Phuong L. and Yatsenko, Alexander and Bellissimo, Daniel and Guo, Fen},
  title = {Improving Hereditary Cancer Risk Assessment: Systematic Reanalysis Supports Multigene Cancer Predisposition Panel Over Single Cancer Panel},
  journal = {Human Mutation},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/humu/6594805}
}
Kostenlos starten →